Literature DB >> 19357543

Lymph node dissection for lung cancer: significance, strategy, and technique.

Shun-ichi Watanabe1, Hisao Asamura.   

Abstract

Since Cahan (1960) reported the first 48 cases that successfully underwent lobectomy with regional lymph node dissection, which was called "radical lobectomy", this procedure was universally accepted and has remained a standard surgery for lung cancer. In recent decades, the intrathoracic reevaluation of disease at thoracotomy for lung cancer has evolved into a detailed and sophisticated assessment of disease extent. Central to this is an evaluation of nodal involvement at the mediastinal and hilar levels. This technique, termed "systematic nodal dissection" (SND), has been accepted by the IASLC to be an important component of intrathoracic staging. In this manuscript, the significance, recent strategy, and technique of lymph node dissection for lung cancer are described.

Entities:  

Mesh:

Year:  2009        PMID: 19357543     DOI: 10.1097/JTO.0b013e31819cce50

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  19 in total

1.  Design and characterization of an optimized simultaneous color and near-infrared fluorescence rigid endoscopic imaging system.

Authors:  Vivek Venugopal; Minho Park; Yoshitomo Ashitate; Florin Neacsu; Frank Kettenring; John V Frangioni; Sidhu P Gangadharan; Sylvain Gioux
Journal:  J Biomed Opt       Date:  2013-12       Impact factor: 3.170

2.  Has lobe-specific nodal dissection for early-stage non-small lung cancer already become standard treatment?

Authors:  Tomohiro Maniwa; Ken Kodama
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  Selective mediastinal lymphadenectomy without intraoperative frozen section examinations for clinical stage I non-small-cell lung cancer: retrospective study of 403 cases.

Authors:  Wei Jiang; Xiaoke Chen; Junjie Xi; Qun Wang
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

4.  Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer.

Authors:  Cristiano Benato; Sara Pilotto; Maurizio Infante; Emilio Bria
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

5.  Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less.

Authors:  Youngkyu Moon; Si Young Choi; Jae Kil Park; Kyo Young Lee
Journal:  World J Surg       Date:  2020-05       Impact factor: 3.352

6.  The clinical value of a new method of functional lymph node dissection in video-assisted thoracic surgery right non-small cell lung cancer radical resection.

Authors:  Sui Chen; Shijie Huang; Shaobin Yu; Ziyang Han; Lei Gao; Zhimin Shen; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

7.  Prognostic factors in stage IB non-small cell lung cancer according to the 8th edition of the TNM staging system after curative resection.

Authors:  Youngkyu Moon; Si Young Choi; Jae Kil Park; Kyo Young Lee
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

8.  Predictors of lymph node metastasis and possible selective lymph node dissection in clinical stage IA non-small cell lung cancer.

Authors:  Ningning Ding; Yousheng Mao; Shugeng Gao; Qi Xue; Dali Wang; Jun Zhao; Yushun Gao; Jinfeng Huang; Kang Shao; Feiyue Feng; Yue Zhao; Ligong Yuan
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

9.  Hyperbaric oxygen therapy for postoperative ischemic bronchitis after resection of lung cancer.

Authors:  Makoto Endoh; Hiroyuki Oizumi; Hirohisa Kato; Jun Suzuki; Hikaru Watarai; Akira Hamada; Katsuyuki Suzuki; Kenta Nakahashi; Satoshi Shiono; Mitsuaki Sadahiro
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

10.  Nodal involvement pattern in resectable lung cancer according to tumor location.

Authors:  Somcharoen Saeteng; Apichat Tantraworasin; Juntima Euathrongchit; Nirush Lertprasertsuke; Yutthaphun Wannasopha
Journal:  Cancer Manag Res       Date:  2012-06-07       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.